149 related articles for article (PubMed ID: 36093532)
41. Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models.
Chen YJ; Wu JY; Deng YY; Wu Y; Wang XQ; Li AS; Wong LY; Fu XQ; Yu ZL; Liang C
J Ginseng Res; 2022 May; 46(3):418-425. PubMed ID: 35600776
[TBL] [Abstract][Full Text] [Related]
42. Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
Wang Y; Pandey M; Ballo MT
Oncologist; 2019 Dec; 24(12):e1426-e1436. PubMed ID: 31444292
[TBL] [Abstract][Full Text] [Related]
43. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
[TBL] [Abstract][Full Text] [Related]
44. Metformin enhances the sensitivity of colorectal cancer cells to cisplatin through ROS-mediated PI3K/Akt signaling pathway.
Zhang P; Zhao S; Lu X; Shi Z; Liu H; Zhu B
Gene; 2020 Jun; 745():144623. PubMed ID: 32222530
[TBL] [Abstract][Full Text] [Related]
45. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line.
Chai H; Luo AZ; Weerasinghe P; Brown RE
Int J Clin Exp Pathol; 2010 Apr; 3(4):408-15. PubMed ID: 20490331
[TBL] [Abstract][Full Text] [Related]
46. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
Yang F; Brown C; Buettner R; Hedvat M; Starr R; Scuto A; Schroeder A; Jensen M; Jove R
Mol Cancer Ther; 2010 Apr; 9(4):953-62. PubMed ID: 20371721
[TBL] [Abstract][Full Text] [Related]
47. Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling.
Wang K; Huang W; Sang X; Wu X; Shan Q; Tang D; Xu X; Cao G
Phytomedicine; 2020 Mar; 68():153191. PubMed ID: 32135457
[TBL] [Abstract][Full Text] [Related]
48. DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Chen X; Yang G; Guo X; Zhang J; Sun W; Liu D; Wang H; Liu S
Oxid Med Cell Longev; 2022; 2022():2543220. PubMed ID: 35770048
[TBL] [Abstract][Full Text] [Related]
49. Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
Wang L; Jia D; Duan F; Sun Z; Liu X; Zhou L; Sun L; Ren S; Ruan Y; Gu J
Biochem Biophys Res Commun; 2012 Jun; 422(4):687-92. PubMed ID: 22634008
[TBL] [Abstract][Full Text] [Related]
50. Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK.
Lee S; Cho YY; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
Int J Mol Med; 2018 Nov; 42(5):2551-2559. PubMed ID: 30106087
[TBL] [Abstract][Full Text] [Related]
51. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
Voloshin T; Kaynan N; Davidi S; Porat Y; Shteingauz A; Schneiderman RS; Zeevi E; Munster M; Blat R; Tempel Brami C; Cahal S; Itzhaki A; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
Cancer Immunol Immunother; 2020 Jul; 69(7):1191-1204. PubMed ID: 32144446
[TBL] [Abstract][Full Text] [Related]
52. Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway.
Ding W; Chen X; Yang L; Chen Y; Song J; Bu W; Feng B; Zhang M; Luo Y; Jia X; Feng L
Integr Cancer Ther; 2022; 21():15347354221078888. PubMed ID: 35234063
[TBL] [Abstract][Full Text] [Related]
53. Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
Wan J; Liu T; Mei L; Li J; Gong K; Yu C; Li W
Br J Cancer; 2013 Jul; 109(2):342-50. PubMed ID: 23807172
[TBL] [Abstract][Full Text] [Related]
54. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
55. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
[TBL] [Abstract][Full Text] [Related]
56. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
Liu J; Liu Y; Meng L; Ji B; Yang D
Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
[No Abstract] [Full Text] [Related]
57. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
[TBL] [Abstract][Full Text] [Related]
58. Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data.
Goldman S; Margol A; Hwang EI; Tanaka K; Suchorska B; Crawford JR; Kesari S
Front Oncol; 2022; 12():958637. PubMed ID: 36072789
[TBL] [Abstract][Full Text] [Related]
59. IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells.
Li Y; Chen G; Han Z; Cheng H; Qiao L; Li Y
Onco Targets Ther; 2020; 13():9721-9730. PubMed ID: 33061451
[TBL] [Abstract][Full Text] [Related]
60. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]